Join Growin Stock Community!

Lb pharmaceuticals inc common stockLBRX.US Overview

US StockHealthcare
(No presentation for LBRX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

LBRX AI Insights

LBRX Overall Performance

LBRX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

LBRX Recent Performance

-2.03%

Lb pharmaceuticals inc common stock

0.05%

Avg of Sector

-0.31%

S&P500

LBRX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

LBRX Key Information

LBRX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

LBRX Profile

Price of LBRX

LBRX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

LBRX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.34
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.98
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.34
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.98
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is LBRX's latest earnings report released?

    The most recent financial report for Lb pharmaceuticals inc common stock (LBRX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating LBRX's short-term business performance and financial health. For the latest updates on LBRX's earnings releases, visit this page regularly.

  • How much debt does LBRX have?

    As of the end of the reporting period, Lb pharmaceuticals inc common stock (LBRX) had total debt of 3.67M, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does LBRX have?

    At the end of the period, Lb pharmaceuticals inc common stock (LBRX) held Total Cash and Cash Equivalents of 270.26M, accounting for 0.84 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is LBRX's EPS continuing to grow?

    According to the past four quarterly reports, Lb pharmaceuticals inc common stock (LBRX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.61. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of LBRX?

    Lb pharmaceuticals inc common stock (LBRX)'s Free Cash Flow (FCF) for the period is -3.37M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 85% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.